The Embedding of D=4 S.G. Into D=11 S.G.

Castellani, Leonardo; Auria, Riccardo D’; Fré, Pietro

doi:10.1142/9789814542388_0044

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody therapies present a potential alternative treatment option to ART and their potential use in the management of HIV infection has been explored in recent years [11][12][13][14][15][16]. Their appeal as pharmaceutical agents stems from their dual functionality, allowing them to utilize host effector functions with the constant region (Fc domain), while targeting specific viral epitopes with their variable region (Fab).…”

Section: Introductionmentioning

confidence: 99%

Engineering strategies of Anti-HIV antibody therapeutics in clinical development

Pihlstrom

Bournazos

2023

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

Purpose of reviewAnti-human immunodeficiency virus (HIV) antibody-based therapeutics offer an alternative treatment option to current antiretroviral drugs. This review aims to provide an overview of the Fc- and Fab-engineering strategies that have been developed to optimize broadly neutralizing antibodies and discuss recent findings from preclinical and clinical studies.Recent findingsMultispecific antibodies, including bispecific and trispecific antibodies, DART molecules, and BiTEs, as well as Fc-optimized antibodies, have emerged as promising therapeutic candidates for the treatment of HIV. These engineered antibodies engage multiple epitopes on the HIV envelope protein and human receptors, resulting in increased potency and breadth of activity. Additionally, Fc-enhanced antibodies have demonstrated extended half-life and improved effector function.SummaryThe development of Fc and Fab-engineered antibodies for the treatment of HIV continues to show promising progress. These novel therapies have the potential to overcome the limitations of current antiretroviral pharmacologic agents by more effectively suppressing viral load and targeting latent reservoirs in individuals living with HIV. Further studies are needed to fully understand the safety and efficacy of these therapies, but the growing body of evidence supports their potential as a new class of therapeutics for the treatment of HIV.

show abstract